dc.contributor.author | Akdeniz, Nadiye | |
dc.contributor.author | Kaplan, Muhammet Ali | |
dc.contributor.author | Kaya, Serap | |
dc.contributor.author | Koral, Lokman | |
dc.date.accessioned | 2024-12-16T06:21:07Z | |
dc.date.available | 2024-12-16T06:21:07Z | |
dc.date.issued | 2021 | en_US |
dc.identifier.citation | Akdeniz, N., Kaplan, M. A., Uncu, D., İnanç, M., Kaya, S., Dane, F., … Işıkdoğan, A. (2021). The comparison of FOLFOX regimens with different doses of 5-FU for the adjuvant treatment of colorectal cancer: a multicenter study. International Journal of Colorectal Disease, 36(6), 1311–1319. https://doi.org/10.1007/s00384-021-03888-9 | en_US |
dc.identifier.issn | 0179-1958 / 1432-1262 | |
dc.identifier.uri | https://doi.org/10.1007/s00384-021-03888-9 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12428/6743 | |
dc.description.abstract | Purpose: We aim to compare the efficiency and toxicity of three different 5-fluorouracil (5-FU) administration types in 5-FU, leucovorin, and oxaliplatin (FOLFOX) combination treatment for adjuvant therapy in colorectal cancer (CRC). Methods: Five hundred and seventy patients with stage III colorectal carcinoma who received different FOLFOX regimens after curative resection were included. Patients were divided into three groups as FOLFOX-4, modified FOLFOX-6 (mFOLFOX-6), and mFOLFOX-4 for comparison of toxicity and disease-free survival (DFS) and overall survival (OS) times. Results: Three-year DFS rates for FOLFOX-4, mFOLFOX-6, and mFOLFOX-4 groups were 65%, 72%, and 72%, respectively. Five-year OS rates for FOLFOX-4, mFOLFOX-6, and mFOLFOX-4 groups were 69%, 75%, and 67%, respectively. There was no statistically significant difference between the three treatment groups in terms of DFS and OS (p = 0.079, and p = 0.147, respectively). Among grade 1–2 adverse events (AE), thrombocytopenia, neuropathy, and stomatitis were more common in the mFOLFOX-6-treated group. The frequency of grade 1–2 nausea and vomiting were similar in mFOLFOX-6 (36.3% and 24%, respectively) and mFOLFOX-4 (32.4% and 24.7%, respectively) groups but were higher than that in the FOLFOX-4 (19.5% and 11.3%, respectively) group. Among the most common grade 3–4 AE, neutropenia (53.4%, 9%, and 13.5%, respectively) and diarrhea (10.5%, 2.2%, and 2.4, respectively) were more common in FOLFOX-4. The rate of anemia and febrile neutropenia was similar in treatment groups (p = 0.063, and p = 0.210, respectively). Conclusion: In the adjuvant treatment of stage III CRC patients, three different 5-FU administration types in FOLFOX combination treatment can be used with similar efficiency and manageable toxicity. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Springer Science and Business Media Deutschland GmbH | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Adjuvant chemotherapy | en_US |
dc.subject | Colorectal cancer | en_US |
dc.subject | FOLFOX regimens | en_US |
dc.subject | Stage III | en_US |
dc.title | The comparison of FOLFOX regimens with different doses of 5-FU for the adjuvant treatment of colorectal cancer: a multicenter study | en_US |
dc.type | article | en_US |
dc.authorid | 0000-0003-4646-4591 | en_US |
dc.relation.ispartof | International Journal of Colorectal Disease | en_US |
dc.department | Fakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü | en_US |
dc.identifier.volume | 36 | en_US |
dc.identifier.issue | 6 | en_US |
dc.institutionauthor | Koral, Lokman | |
dc.identifier.doi | 10.1007/s00384-021-03888-9 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.authorwosid | HLE-3968-2023 | en_US |
dc.authorscopusid | 12783716500 | en_US |
dc.identifier.wosquality | Q1 | en_US |
dc.identifier.wos | WOS:000617829700001 | en_US |
dc.identifier.scopus | 2-s2.0-85101043431 | en_US |
dc.identifier.pmid | PMID: 33586012 | en_US |